Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 68

1.

Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1.

McColley SA, Konstan MW, Ramsey BW, Stuart Elborn J, Boyle MP, Wainwright CE, Waltz D, Vera-Llonch M, Marigowda G, Jiang JG, Rubin JL.

J Cyst Fibros. 2018 Aug 23. pii: S1569-1993(18)30719-7. doi: 10.1016/j.jcf.2018.07.011. [Epub ahead of print]

2.

Cystic fibrosis year in review 2017.

Savant AP, McColley SA.

Pediatr Pulmonol. 2018 Sep;53(9):1307-1317. doi: 10.1002/ppul.24081. Epub 2018 Jun 21. Review.

PMID:
29927544
3.

Designing trials for new cystic fibrosis modulators.

Cunningham S, McColley SA.

Lancet Respir Med. 2018 Jul;6(7):484-486. doi: 10.1016/S2213-2600(18)30195-4. Epub 2018 May 31. No abstract available.

PMID:
29859920
4.

Are children with chronic illnesses requiring dietary therapy at risk for disordered eating or eating disorders? A systematic review.

Conviser JH, Fisher SD, McColley SA.

Int J Eat Disord. 2018 Mar;51(3):187-213. doi: 10.1002/eat.22831. Epub 2018 Feb 22. Review.

PMID:
29469935
5.

The relationship between sweat chloride levels and mortality in cystic fibrosis varies by individual genotype.

Espel JC, Palac HL, Bharat A, Cullina J, Prickett M, Sala M, McColley SA, Jain M.

J Cyst Fibros. 2018 Jan;17(1):34-42. doi: 10.1016/j.jcf.2017.11.002. Epub 2017 Dec 6.

PMID:
29221674
6.

Antibiotic duration and changes in FEV1 are not associated with time until next exacerbation in adult cystic fibrosis: a single center study.

Espel JC, Palac HL, Cullina JF, Clarke AP, McColley SA, Prickett MH, Jain M.

BMC Pulm Med. 2017 Nov 29;17(1):160. doi: 10.1186/s12890-017-0503-6.

7.

Airway microbiota across age and disease spectrum in cystic fibrosis.

Zemanick ET, Wagner BD, Robertson CE, Ahrens RC, Chmiel JF, Clancy JP, Gibson RL, Harris WT, Kurland G, Laguna TA, McColley SA, McCoy K, Retsch-Bogart G, Sobush KT, Zeitlin PL, Stevens MJ, Accurso FJ, Sagel SD, Harris JK.

Eur Respir J. 2017 Nov 16;50(5). pii: 1700832. doi: 10.1183/13993003.00832-2017. Print 2017 Nov.

8.

The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.

Talamo Guevara M, McColley SA.

Expert Opin Drug Saf. 2017 Nov;16(11):1305-1311. doi: 10.1080/14740338.2017.1372419. Epub 2017 Sep 21. Review.

9.

Cystic fibrosis year in review 2016.

Savant AP, McColley SA.

Pediatr Pulmonol. 2017 Aug;52(8):1092-1102. doi: 10.1002/ppul.23747. Epub 2017 Jun 13. Review.

PMID:
28608632
10.

Risk factors for mortality before age 18 years in cystic fibrosis.

McColley SA, Schechter MS, Morgan WJ, Pasta DJ, Craib ML, Konstan MW.

Pediatr Pulmonol. 2017 Jul;52(7):909-915. doi: 10.1002/ppul.23715. Epub 2017 Apr 24.

PMID:
28436621
11.

Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation.

Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, Howenstine M, McColley SA, Rock M, Rosenfeld M, Sermet-Gaudelus I, Southern KW, Marshall BC, Sosnay PR.

J Pediatr. 2017 Feb;181S:S4-S15.e1. doi: 10.1016/j.jpeds.2016.09.064.

12.

Diagnosis of Cystic Fibrosis in Screened Populations.

Farrell PM, White TB, Howenstine MS, Munck A, Parad RB, Rosenfeld M, Sommerburg O, Accurso FJ, Davies JC, Rock MJ, Sanders DB, Wilschanski M, Sermet-Gaudelus I, Blau H, Gartner S, McColley SA.

J Pediatr. 2017 Feb;181S:S33-S44.e2. doi: 10.1016/j.jpeds.2016.09.065.

13.

Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.

Rowe SM, McColley SA, Rietschel E, Li X, Bell SC, Konstan MW, Marigowda G, Waltz D, Boyle MP; VX09-809-102 Study Group.

Ann Am Thorac Soc. 2017 Feb;14(2):213-219. doi: 10.1513/AnnalsATS.201609-689OC.

14.
15.

Aminoglycoside resistance of Pseudomonas aeruginosa in cystic fibrosis results from convergent evolution in the mexZ gene.

Prickett MH, Hauser AR, McColley SA, Cullina J, Potter E, Powers C, Jain M.

Thorax. 2017 Jan;72(1):40-47. doi: 10.1136/thoraxjnl-2015-208027. Epub 2016 Jun 20.

16.

Pediatric Pulmonology year in review 2015: Part 4.

Savant AP, McColley SA.

Pediatr Pulmonol. 2016 Jul;51(7):754-65. doi: 10.1002/ppul.23470. Epub 2016 May 12. Review.

PMID:
27171478
17.

A safety evaluation of ivacaftor for the treatment of cystic fibrosis.

McColley SA.

Expert Opin Drug Saf. 2016 May;15(5):709-15. doi: 10.1517/14740338.2016.1165666. Epub 2016 Apr 7. Review.

PMID:
26968005
18.

Refining the continuum of CFTR-associated disorders in the era of newborn screening.

Levy H, Nugent M, Schneck K, Stachiw-Hietpas D, Laxova A, Lakser O, Rock M, Dahmer MK, Biller J, Nasr SZ, Baker M, McColley SA, Simpson P, Farrell PM.

Clin Genet. 2016 May;89(5):539-49. doi: 10.1111/cge.12711. Epub 2016 Jan 20.

19.

Sorting out the gray zone: Cystic fibrosis newborn screening.

McColley SA.

J Cyst Fibros. 2015 Nov;14(6):681-2. doi: 10.1016/j.jcf.2015.10.003. Epub 2015 Oct 21. No abstract available.

20.

2014 year in review: Cystic fibrosis.

Savant AP, McColley SA.

Pediatr Pulmonol. 2015 Nov;50(11):1147-56. doi: 10.1002/ppul.23309. Epub 2015 Sep 7. Review.

PMID:
26347000

Supplemental Content

Loading ...
Support Center